Other languages ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Real-time Estimate Cboe BZX Other stock markets 20:40:56 29/04/2024 BST			5-day change	1st Jan Change
8.745 ^USD	+18.98%		+76.51%	+73.70%

05:06pm	Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating	MT
12:52pm	Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	11:52am
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	04-25
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	04-23
IN DIRETTA DAI MERCATI: Netweek, Ence Energia, Enel, OVS, Sogefi, Telecom Italia, ASML, Novartis, Airbus, Apple, Nvidia, Boeing...	04-23
C'est parti pour les publications de résultats à la chaîne	04-23
En Direct des Marchés : Renault, SAP, Sanofi, TotalEnergies, Novartis, Legrand, Tapestry, OVH...	04-23
EN DIRECTO DESDE LOS MERCADOS: Enagas, Ence Energia, Acerinox, Naturgy, Endesa, Telefónica, Novartis, Apple, Nvidia, Boeing...	04-23
Bolsa de Madrid: Publicación consecutiva de resultados	04-23
US FDA approves ImmunityBio's bladder cancer therapy	04-23
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	04-23
U.S. FDA approves ImmunityBio's bladder cancer therapy	04-22
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19
ImmunityBio Announces Data from A Phase 1 Pilot Study	03-05
ImmunityBio Says Cancer Vaccine Trial Moving to Controlled Phase	02-21
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	02-21
Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG	02-05
US Equity Markets Close Lower Tuesday Ahead of Fed Meeting Minutes	01-02
Sector Update: Health Care Stocks Gain Late Afternoon	01-02
Sector Update: Health Care Stocks Rise Tuesday Afternoon	01-02
ImmunityBio Secures $320 Million Investment From Oberland Capital	01-02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Other languages

Filters